Science Stories
Science Stories
Search
Be green Japan
Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
Careers beyond borders
Careers beyond borders
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Main Meal
You can browse through all of the filling main meal recipes from Taking Cancer on Through Flavour here.
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Telling my story AF and DVT PE Patient Voices
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Meet our team
Meet our team
Cat care interview veterinarian Dr Susan Little
World-renowned feline healthcare specialist Dr. Susan Little shares her thoughts on latest trends in cat care.
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Ruminants
Ruminants
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Cities join forces for stroke care improvements
Learn how Angels Cities unite to swiftly address stroke symptoms. Quick collaboration saves crucial minutes, minimizing stroke’s devastating effects.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Pioneering for progress in generalized pustular psoriasis
An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP
Mental health: a $1 trillion burden demanding policy action
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Professor Gregory Lip introduces the GLORIA™-AF Registry
Partnership African animal trypanosomiasis
New partnership working on solutions to combat African animal trypanosomiasis
Research Collaborations
Research Collaborations